Pulling SEC filings + quote and writing the call…

Oncology Institute, Inc.
Next earnings Aug 11, 2026 · consensus $-0.07 EPS, $159M rev
Last earnings +7.1% on 2026-05-07
Revenue grew 27.8% YoY; but unprofitable (net margin -12.1%).
Oncology Institute, Inc. shows $503M in FY2025 revenue (+27.8% YoY), a -12.1% net margin.
Sources: SEC EDGAR (CIK 0001799191, latest 10-Q filed 2026-05-07) · EODHD · as of 6/25/2026, 5:40:19 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $203M | $252M | $324M | $393M | $503M |
| Gross profit | — | — | — | — | — |
| Operating income | -$45.9M | -$82.0M | -$77.0M | -$60.1M | -$36.1M |
| Net income | -$10.9M | $152K | -$83.1M | -$64.7M | -$60.6M |
| Diluted EPS | -$0.16 | -$0.21 | -$0.92 | -$0.71 | -$0.54 |
| Net margin | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1079 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 5 open-market buys · 1 sale
| 2026-06-23 | Chernett Jorey 10% owner | Buy | 18.0K @ $5.02 | $90.4K |
| 2026-06-08 | Podnos Yale Chief Medical Officer | Sell | 23.5K @ $5.38 | $126K |
| 2026-06-04 | Chernett Jorey 10% owner | Buy | 12.0K @ $4.75 | $57.0K |
| 2026-05-21 | Podnos Yale Chief Medical Officer | Disposed (J) | 1.80K @ $4.47 | $8.07K |
| 2026-05-21 | Virnich Daniel Chief Executive Officer | Disposed (J) | 23.1K @ $4.47 | $103K |
| 2026-05-21 | Carter Robert Ross Chief Financial Officer | Disposed (J) | 1.60K @ $4.47 | $7.17K |
| 2026-05-20 | Chernett Jorey 10% owner | Buy | 33.5K @ $4.07 | $136K |
| 2026-05-19 | Chernett Jorey 10% owner | Buy | 5.00K @ $4.05 | $20.3K |
| 2026-05-19 | Chernett Jorey 10% owner | Buy | 30.0K @ $4.09 | $123K |